STAT3 Signaling Pathway in Health and Disease
MedComm · 2025-04 · 6 (4)
DOI: 10.1002/mco2.70152 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 30.03.2025. Verfasst von Md Abdus Samad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry Faculty of Science King Abdulaziz University Jeddah Saudi Arabia. Die Arbeit wurde bisher 140-mal zitiert (Crossref) und nennt 390 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Signal transducer and activator of transcription 3 (STAT3) is a critical transcription factor involved in multiple physiological and pathological processes. While STAT3 plays an essential role in homeostasis, its persistent activation has been implicated in the pathogenesis of various diseases, particularly cancer, bone‐related diseases, autoimmune disorders, inflammatory diseases, cardiovascular diseases, and neurodegenerative conditions. The interleukin‐6/Janus kinase (JAK)/STAT3 signaling axis is central to STAT3 activation, influencing tumor microenvironment remodeling, angiogenesis, immune evasion, and therapy resistance. Despite extensive research, the precise mechanisms underlying dysregulated STAT3 signaling in disease progression remain incompletely understood, and no United States Food and Drug Administration (USFDA)‐approved direct STAT3 inhibitors currently exist. This review provides a comprehensive evaluation of STAT3's role in health and disease, emphasizing its involvement in cancer stem cell maintenance, metastasis, inflammation, and drug resistance. We systematically discuss therapeutic strategies, including JAK inhibitors (tofacitinib, ruxolitinib), Src Homology 2 domain inhibitors (S3I‐201, STATTIC), antisense oligonucleotides (AZD9150), and nanomedicine‐based drug delivery systems, which enhance specificity and bioavailability while reducing toxicity. By integrating molecular mechanisms, disease pathology, and emerging therapeutic interventions, this review fills a critical knowledge gap in STAT3‐targeted therapy. Our insights into STAT3 signaling crosstalk, epigenetic regulation, and resistance mechanisms offer a foundation for developing next‐generation STAT3 inhibitors with greater clinical efficacy and translational potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry Faculty of Science King Abdulaziz University Jeddah Saudi Arabia.
- King Fahd Medical Research Center King Abdulaziz University Jeddah Saudi Arabia.
- Department of Biochemistry Faculty of Life Science Aligarh Muslim University Aligarh India.
- Department of Medical Laboratory Sciences Faculty of Applied Medical Sciences King Abdulaziz University Jeddah Saudi Arabia.
- Department of Medicine College of Health Sciences University of Georgia Georgia USA.
- Department of Chemistry College of Arts and Sciences International University of Business Agriculture & Technology (IUBAT) Dhaka Bangladesh.
ORCID-Profile: Shams Tabrez
Zitieren
APA
Samad, M. A., Ahmad, I., Hasan, A., Alhashmi, M. H., Ayub, A., Al-Abbasi, F. A., Kumer, A., & Tabrez, S. (2025). STAT3 Signaling Pathway in Health and Disease. MedComm, 6(4). https://doi.org/10.1002/mco2.70152
Vancouver
Samad MA, Ahmad I, Hasan A, Alhashmi MH, Ayub A, Al-Abbasi FA, et al. STAT3 Signaling Pathway in Health and Disease. MedComm. 2025;6(4). doi:10.1002/mco2.70152
BibTeX
@article{Samad2025,
author = {Samad, Md Abdus and Ahmad, Iftikhar and Hasan, Aakifah and Alhashmi, Mohammad Hassan and Ayub, Arusha and Al-Abbasi, Fahad A and Kumer, Ajoy and Tabrez, Shams},
title = {STAT3 Signaling Pathway in Health and Disease},
journal = {MedComm},
year = {2025},
volume = {6},
number = {4},
doi = {10.1002/mco2.70152}
}
EUVIMED